OBJECTIVES: We investigated how persons from key populations at higher risk of HIV exposure interpreted the process and outcomes of the Step Study HIV-1 vaccine trial, which was terminated early, and implications for willingness to participate in and community support for HIV vaccine research. METHODS: We used qualitative methods and a community-based approach in 9 focus groups (n = 72) among ethnically and sexually diverse populations and 6 semistructured key informant interviews in Ontario, Canada, in 2007 to 2008. RESULTS: Participants construed social meaning from complex clinical and biomedical phenomena. Social representations and mental models emerged in fears of vaccine-induced infection, conceptualizations of unfair recruitment practices and increased risk behaviors among trial participants, and questioning of informed consent. Narratives of altruism and the common good demonstrated support for future trials. CONCLUSIONS: Public discourse on HIV vaccine trials is a productive means of interpreting complex clinical trial processes and outcomes in the context of existing beliefs and experiences regarding HIV vaccines, medical research, and historical disenfranchisement. Strategic engagement with social representations and mental models may promote meaningful community involvement in biomedical HIV prevention research.
OBJECTIVES: We investigated how persons from key populations at higher risk of HIV exposure interpreted the process and outcomes of the Step Study HIV-1 vaccine trial, which was terminated early, and implications for willingness to participate in and community support for HIV vaccine research. METHODS: We used qualitative methods and a community-based approach in 9 focus groups (n = 72) among ethnically and sexually diverse populations and 6 semistructured key informant interviews in Ontario, Canada, in 2007 to 2008. RESULTS:Participants construed social meaning from complex clinical and biomedical phenomena. Social representations and mental models emerged in fears of vaccine-induced infection, conceptualizations of unfair recruitment practices and increased risk behaviors among trial participants, and questioning of informed consent. Narratives of altruism and the common good demonstrated support for future trials. CONCLUSIONS: Public discourse on HIV vaccine trials is a productive means of interpreting complex clinical trial processes and outcomes in the context of existing beliefs and experiences regarding HIV vaccines, medical research, and historical disenfranchisement. Strategic engagement with social representations and mental models may promote meaningful community involvement in biomedical HIV prevention research.
Authors: Dennis R Burton; Ronald C Desrosiers; Robert W Doms; Mark B Feinberg; Robert C Gallo; Beatrice Hahn; James A Hoxie; Eric Hunter; Bette Korber; Alan Landay; Michael M Lederman; Judy Lieberman; Joseph M McCune; John P Moore; Neal Nathanson; Louis Picker; Douglas Richman; Charles Rinaldo; Mario Stevenson; David I Watkins; Steven M Wolinsky; Jerome A Zack Journal: Science Date: 2004-01-16 Impact factor: 47.728
Authors: Robert Belshe; Genoveffa Franchini; Marc P Girard; Frances Gotch; Pontiano Kaleebu; Marta L Marthas; Michael B McChesney; Rose McCullough; Fred Mhalu; Dominique Salmon-Ceron; Rafick-Pierre Sekaly; Koen van Rompay; Bernard Verrier; Britta Wahren; Mercedes Weissenbacher Journal: Science Date: 2004-07-09 Impact factor: 47.728
Authors: Edward Mills; Curtis Cooper; Gordon Guyatt; Amy Gilchrist; Beth Rachlis; Chris Sulway; Kumanan Wilson Journal: AIDS Date: 2004-11-19 Impact factor: 4.177
Authors: Karine Dubé; Jane Simoni; Michael Louella; Laurie Sylla; Zahra H Mohamed; Hursch Patel; Stuart Luter; Ann C Collier Journal: AIDS Res Hum Retroviruses Date: 2019-05-21 Impact factor: 2.205
Authors: Laurie Sylla; David Evans; Jeff Taylor; Adam Gilbertson; David Palm; Judith D Auerbach; Karine Dubé Journal: AIDS Res Hum Retroviruses Date: 2018-01 Impact factor: 2.205
Authors: Peter A Newman; Clara Rubincam; Catherine Slack; Zaynab Essack; Venkatesan Chakrapani; Deng-Min Chuang; Suchon Tepjan; Murali Shunmugam; Surachet Roungprakhon; Carmen Logie; Jennifer Koen; Graham Lindegger Journal: PLoS One Date: 2015-08-21 Impact factor: 3.240
Authors: Elizabeth E Tolley; Kate Morrow Guthrie; Seth Zissette; Joseph L Fava; Katherine Gill; Cheryl E Louw; Philip Kotze; Krishnaveni Reddy; Kathleen MacQueen Journal: PLoS One Date: 2018-04-12 Impact factor: 3.240